Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria: A Multisite Clinical, Molecular and Phenotypic Study Across Five Sentinel Sites in Ethiopia, 2024-2025

NCT07527182 is registered in ClinicalTrials.gov with Didier Menard as lead sponsor.

NCT NCT07527182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07527182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria: A Multisite Clinical, Molecular and Phenotypic Study Across Five Sentinel Sites in Ethiopia, 2024-2025
Lead sponsor
Didier Menard
Phase
Not applicable
Overall status
Completed
Start date
May 1, 2024
Completion date
April 7, 2026
Enrollment
277 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

artemisinin-resistant, drug resistance, ethiopia, malaria (plasmodium falciparum)